Last reviewed · How we verify
GLP-1 medication
The Cleveland Clinic's GLP-1 medication is currently marketed, positioning it as an established player in the diabetes and weight management space. A key strength is the protection of its core composition patent, which does not expire until 2028, providing a significant period of market exclusivity. The primary risk is the lack of disclosed revenue data, which may limit the ability to assess its commercial performance and competitive standing.
At a glance
| Generic name | GLP-1 medication |
|---|---|
| Also known as | Tirzepatide, Semaglutide, Liraglutide, Dulaglutide |
| Sponsor | The Cleveland Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- Semaglutide Use in Acute Pulmonary Embolism
- Tirzepatide to Slow Biological Aging (PHASE2)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists (NA)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLP-1 medication CI brief — competitive landscape report
- GLP-1 medication updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI